Irisin is a myokine derived from fibronectin type III domain containing 5 (FNDC5) released into the circulation during physical exercise. It is known that FNDC5/irisin stimulates brain-derived neurotrophic factor (BDNF) expression in the hippocampus and also that Alzheimer’s disease (AD) models and brains and cerebrospinal fluid of AD patients have low levels of irisin.
Lapix Therapeutics Inc. has received IND clearance from the FDA to initiate a phase I trial of its first-in-class, immune tolerance restoration small molecule, LPX-TI641, for the treatment of multiple sclerosis (MS).
Evaxion Biotech A/S has announced the initiation of a novel pipeline program, EVX-B3, an artificial intelligence (AI)-designed vaccine candidate against an undisclosed bacterial pathogen. The new vaccine project will be the subject of a co-funded collaboration between Evaxion and an undisclosed partner.
Researchers from China Pharmaceutical University and Nanjing First Hospital synthesized and optimized a novel series of thiohydantoin based compounds leading to the discovery of candidate [I] as the lead androgen receptor (AR) antagonist (IC50=1.46 µM).
Transforming growth factor β1 (TGF-β1) is a key mediator of the fibrotic response, and its dysregulation drives the formation of the fibrotic niche, which impairs the capacity of tissue repair, regeneration and homeostasis.
The development of novel antimicrobial agents is crucial to combat the emergence of multidrug-resistant bacteria, which cause millions of deaths and high economic losses. Researchers from Shaanxi University of Science & Technology and colleagues reported on the design and optimization of new pleuromutilin derivatives intended for use as antibacterial drugs against multidrug-resistant gram-negative bacteria.
Researchers at Ontario Institute for Cancer Research and Sunnybrook Research Institute have described isoquinoline derivatives acting as apoptosis regulator BAX and/or BAK inhibitors reported to be useful for the treatment of neurodegenerative disorders.
Insusense ApS has identified sortilin (NT3; Gp95) antagonists reported to be useful for the treatment of neurodegeneration, cancer, pain, diabetes, diabetic retinopathy, glaucoma, hearing loss and cardiovascular disorders, among others.
RSS
